Lapatinib
- 1 June 2007
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 6 (6), 431-432
- https://doi.org/10.1038/nrd2332
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancerAnnals of Oncology, 2007
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast CancerThe New England Journal of Medicine, 2006
- Lapatinib: Current Status and Future Directions in Breast CancerThe Oncologist, 2006
- Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center ExperienceJournal of Clinical Oncology, 2006
- HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based TherapyThe Oncologist, 2006
- Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer CellsCancer Research, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancerBritish Journal of Cancer, 2004
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987